KRN7000

KRN7000 is a synthetic glycolipid that was first developed by the pharmaceutical company KIRIN in Japan. It is a type of alpha-galactosylceramide (α-GalCer), which is a glycolipid antigen that can stimulate Natural Killer T cells (NKT cells).

History

KRN7000 was first synthesized in the 1990s by KIRIN as part of their research into potential treatments for autoimmune diseases and cancer. The compound was derived from a marine sponge called Agelas mauritianus, which is known to produce a variety of bioactive compounds.

Mechanism of Action

KRN7000 works by binding to the CD1d molecule on the surface of antigen-presenting cells. This binding event triggers the activation of NKT cells, which are a type of immune cell that plays a crucial role in the body's response to infection and disease. Once activated, NKT cells can produce a range of cytokines that help to regulate the immune response.

Clinical Applications

Research into the potential clinical applications of KRN7000 is ongoing. Early studies have suggested that it may have potential as a treatment for a range of conditions, including autoimmune diseases, cancer, and infectious diseases. However, further research is needed to fully understand the potential benefits and risks of this compound.

See Also

• Glycolipid
• Natural Killer T cells
• CD1d
• Cytokines